Two months after disclosing a plan to raise $16.2 million in a stock offering, Avanir Pharmaceuticals Inc. said it's packing in another $20 million, having gained commitments from buyers of 6 million Class A shares at $3.35 each. (BioWorld Today)

In what could become one of the top acquisitions of 2005, Amgen Inc. offered to acquire Abgenix Inc. for $22.50 a share - or about $2.2 billion in cash. (BioWorld Today)